These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Feriozzi S; Schwarting A; Sunder-Plassmann G; West M; Cybulla M; Am J Nephrol; 2009; 29(5):353-61. PubMed ID: 18974635 [TBL] [Abstract][Full Text] [Related]
43. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up]. Lidove O; Bekri S; Goizet C; Khau Van Kien A; Aractingi S; Knebelmann B; Choukroun G; Tsimaratos M; Redonnet-Vernhet I; Lacombe D; Jaussaud R Presse Med; 2007; 36(7-8):1084-97. PubMed ID: 17276649 [TBL] [Abstract][Full Text] [Related]
44. Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Hegemann S; Hajioff D; Conti G; Beck M; Sunder-Plassmann G; Widmer U; Mehta A; Keilmann A Eur J Clin Invest; 2006 Sep; 36(9):654-62. PubMed ID: 16919049 [TBL] [Abstract][Full Text] [Related]
50. Enzyme therapy XVII: metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease. Desnick RJ; Dean KJ; Grabowski GA; Bishop DF; Sweeley CC Birth Defects Orig Artic Ser; 1980; 16(1):393-413. PubMed ID: 6256019 [TBL] [Abstract][Full Text] [Related]
51. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring. Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437 [TBL] [Abstract][Full Text] [Related]
52. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782 [TBL] [Abstract][Full Text] [Related]
53. Biomarkers of Fabry disease nephropathy. Schiffmann R; Waldek S; Benigni A; Auray-Blais C Clin J Am Soc Nephrol; 2010 Feb; 5(2):360-4. PubMed ID: 19965549 [TBL] [Abstract][Full Text] [Related]
54. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Kitagawa T; Ishige N; Suzuki K; Owada M; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Mills K; Winchester B; Keutzer J Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031 [TBL] [Abstract][Full Text] [Related]
55. [Fabry disease--diagnostic guideline]. Constantin T; Rákóczi E; Ponyi A; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Csikós M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G; Orv Hetil; 2010 Feb; 151(7):243-9. PubMed ID: 20133243 [TBL] [Abstract][Full Text] [Related]
57. Early therapeutic intervention in females with Fabry disease? Hughes DA Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187 [TBL] [Abstract][Full Text] [Related]
58. [Fabry disease]. Jakubowska E; Ryba M; Hruby Z Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745 [TBL] [Abstract][Full Text] [Related]
59. Hemizygous Fabry disease associated with IgA nephropathy: a case report. Shimohata H; Yoh K; Takada K; Tanaka H; Usui J; Hirayama K; Kobayashi M; Yamagata K J Nephrol; 2009; 22(5):682-4. PubMed ID: 19810002 [TBL] [Abstract][Full Text] [Related]
60. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS). Barba-Romero MÁ; Rivera-Gallego A; Pintos-Morell G; Int J Clin Pract; 2011 Aug; 65(8):903-10. PubMed ID: 21679285 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]